Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.
Authors
Masafumi Ikeda
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan;
Masafumi Ikeda , Shinji Itoh , Ryosuke Tateishi , Tatsuya Yamashita , Takuji Okusaka , Naoya Kato , Junji Furuse , Masatoshi Kudo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000040488
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 566)
DOI
10.1200/JCO.2023.41.4_suppl.566
Abstract #
566
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
First Author: Stephen Chan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC).
First Author: David Edward Kaplan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.
First Author: Yoshinari Asaoka
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Incidence and costs associated with clinically significant events in real-world patients with unresectable hepatocellular carcinoma on systemic therapy.
First Author: Marcus Healey